Table 1 Clinical course of patients, in whom SEI developed after EKC, that were treated with topical 0.05% CSA eye drops
Patient | Age/Sex | Affected eye | Initial BCVA (LogMAR) | Initial IOP (mmHg) | Initial CSIS | Duration of follow up with Corticosteroids Therapy (month) | CsA treatment for increased ocular pressure (Yes/No) | Duration of follow up with 0.05% CSA Therapy (month) | BCVA at last follow-up visit | IOP at last follow-up visit | CSIS at last follow-up visit | The length of follow up without CsA (month) | Recurrence after CsA treatment (Yes/No) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 13/F | RE | 0.00 | 11 | 1 | 12 | Y | 1 | 0.00 | 11 | 0 | 6 | N |
2 | 38/F | LE | 0.00 | 14 | 1 | 9 | N | 6 | 0.00 | 12 | 0 | 5 | N |
3 | 26/F | RE/LE | 0.10/0.22 | 16/18 | 1/2 | 3/5 | N | 1/1 | 0.00/0.10 | 14/19 | 0/0 | 4/3 | N |
4 | 47/F | RE | 0.00 | 15 | 1 | 3 | N | 7 | 0.00 | 17 | 0 | 2 | N |
5 | 40/F | RE | 0.22 | 25 | 1 | 3 | Y | 1 | 0.00 | 20 | 0 | 4 | N |
6 | 30/M | RE/LE | 0.40/0.00 | 26/22 | 4/1 | 4/7 | Y | 13/8 | 0.20/0.00 | 21/19 | 2/0 | 5/3 | N |
7 | 18/M | RE | 0.40 | 23 | 3 | 6 | Y | 7 | 0.15 | 20 | 1 | 2 | N |
8 | 50/M | RE | 0.22 | 18 | 2 | 7 | N | 6 | 0.10 | 16 | 1 | 0 | N |
9 | 27/M | RE/LE | 0.00/0.30 | 15/17 | 1/3 | 8/9 | N | 1/1 | 0.00/0.15 | 13/16 | 0/0 | 3/3 | N |
10 | 40/F | LE | 0.00 | 19 | 2 | 4 | N | 7 | 0.00 | 19 | 0 | 3 | Y |
11 | 16/M | RE | 0.00 | 17 | 1 | 3 | N | 6 | 0.00 | 14 | 0 | 4 | N |
12 | 32/F | RE | 0.20 | 16 | 1 | 3 | N | 1 | 0.10 | 17 | 0 | 3 | N |
13 | 75/M | RE/LE | 0.00/0.20 | 15/22 | 1/2 | 5/4 | Y | 7/8 | 0.00/0.15 | 16/19 | 0/0 | 4/3 | Y |
14 | 60/F | RE | 0.00 | 20 | 1 | 11 | Y | 6 | 0.00 | 19 | 0 | 10 | N |
15 | 30/F | RE/LE | 0.40/0.30 | 17/21 | 3/2 | 13/8 | N | 10/8 | 0.20/0.10 | 15/18 | 1/0 | 12/3 | N |
16 | 22/F | RE/LE | 0.00/0.30 | 17/23 | 1/2 | 14/10 | Y | 1/5 | 0.00/0.10 | 17/19 | 0/0 | 6/4 | N |